1.An Exploratory Study Mitochondrial DNA Deletion and its Relationship to Noise-Induced Hearing Loss
Yue WANG ; Jiaying ZHANG ; Yudan HAN ; Yulan LI
Journal of Audiology and Speech Pathology 1998;0(02):-
Objective To analyze the possible effects of mitochondrial DNA mutation on noise-induced hearing loss.Methods 265 young workers with noise exposure were examined.The average pure tone thresholds at 500,1 000,and 2 000 Hz for 25 voluntary persons were noise-induced hearing loss by nature and selected as the study group.27 voluntary persons with no speech frequency hearing loss were chosen as the control group.DNA was extracted from peripheral blood leukocytes.Polymerase chain reaction(PCR) was used to detect the mtDNA4977 deletion in both groups.Results The detection rate of mtDNA4977 deletion in the study group was 20%(5/25) and it was 0(0/27) for the control group.Conclusion MtDNA4977 deletion in the study group was significantly higher than that of the control group,indicating that mtDNA4977 deletion may play an important role in the development of noise-induced hearing loss.
2.Clinical analysis of endometrial lesions in patients with breast cancer taking tamoxifen after surgery
Xianghua YIN ; Xiling HAN ; Jun GAO ; Jiali LUO ; Yudan ZHENG ; Yehua JING ; Ling ZHAO ; Xueshu FU ; Yanjun YU ; Yaping YE
Cancer Research and Clinic 2018;30(10):682-685
Objective To study the effect of menopause status and the time of taking tamoxifen (TAM) on endometrial lesions after breast cancer surgery. Methods A total of 330 patients with postoperative vaginal irregular bleeding after breast cancer surgery or endometrial lesions after B ultrasonic from August 2007 to August 2017 in Northern Jiangsu People 's Hospital were retrospectively analyzed, including 180 cases of taking TAM treatment (medicine-taking group), and 150 cases of not taking TAM treatment (non medicine-taking group). The patients were also divided into the menopause group and the premenopausal group. According to the time of taking TAM, the patients were divided into < 2 years group, 2-5 years group and > 5 years group. Chi-square and Fisher test were used to compare the differences. Results The endometrial lesions incidence in the medicine-taking group was higher than that in the non medicine-taking group [84.44 % (152/180) vs. 56.00%(84/150);χ2=51.701, P=0.000]. The endometrial lesions rate in the menopause group was higher than that in the premenopause group [medicine-taking group: 69.70 % (46/66) vs. 92.98 % (106/114), χ2= 17.254, P= 0.000; non medicine-taking group: 46.15 % (35/65) vs. 63.53 %(54/85), χ2 = 4.513, P= 0.034]. For the patients in the menopause group and the premenopause group, the incidence of endometrial lesions for those who took medicine for>5 years [96.00%(48/50), 85.19%(23/27)] was higher than that in the<2 years group and 2-5 years group [78.26%(18/23), 42.86%(6/14);95.12%(39/41), 72.00%(18/25) respectively], and there were statistical differences (χ2=7.619, P=0.022;χ2= 8.070, P= 0.018). The menopause was not correlated with staging, muscular lawyer infiltration and lymph metastasis postoperative (P> 0.05), but with the type of endometrial cancer (P= 0.013); the length of taking medicine was related with the type of endometrial cancer and the lymph metastasis (P=0.027). With the prolonged time of medicine-taking for postmenopause patients, the incidence of type Ⅱendometrial cancer and positive rate of lymph metastasis were also increased. Conclusions Taking TAM after surgery for breast cancer patients increases the risk of endometrial lesions. The longer the patients take the medicine, the greater risk of the lesions take, and the worse the pathological, histological type and prognosis of endometrial carcinoma are, which is more obvious for postmenopausal women who take TAM for more than 5 years.